Andrew Gerry
Family · West Linn, ORNPI 1114232576
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,171, 2.6 times the $835 reported in 2021. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Novo Nordisk$510
- GSK$439
- AstraZeneca$351
- Otsuka America Pharmaceutical, Inc.$346
- plus $3K from 36 others
What the payments were for
- Food & beverage$7,29099%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,370 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $53,458 |
| MounjaroTirzepatide | 31 | $33,178 |
| JardianceEmpagliflozin | 17 | $19,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,206 |
| Rosuvastatin Calcium | 72 | $1,011 |
| Atorvastatin Calcium | 75 | $967 |
| Metoprolol Succinate | 39 | $869 |
| Losartan Potassium | 85 | $726 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $619 |
| Metformin Hcl ErMetformin Hcl | 59 | $618 |
| Bupropion XlBupropion Hcl | 25 | $592 |
| Montelukast Sodium | 34 | $556 |
| Omeprazole | 30 | $554 |
| Levothyroxine Sodium | 43 | $529 |
| Amlodipine Besylate | 61 | $506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $510 | $53,45854 claims |
| Lilly USA, LLCMounjaro | $332 | $33,17831 claims |
| Boehringer IngelheimJardiance | $24 | $19,50717 claims |
| GSKTrelegy Ellipta | $439 | $9,20612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in West Linn
- Rachel PulverWest Linn$4K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.